Government // Mobile & Wireless
News
9/23/2013
04:03 PM
Connect Directly
Twitter
RSS
E-Mail
50%
50%

FDA Reveals Final Mobile Health App Guidelines

Agency's tiered approach puts regulatory emphasis on high-risk apps.

Remote Patient Monitoring: 9 Promising Technologies
Remote Patient Monitoring: 9 Promising Technologies
(click image for larger view)
The Food and Drug Administration issued final guidelines for mobile health apps Monday, outlining the apps that the regulations will affect and the requirements those apps must meet to achieve FDA approval.

The FDA's tailored approach focuses on regulating apps that carry significant risks if they aren't operated correctly, such as apps intended to be used as an accessory to a regulated device or apps that transform a mobile platform into a regulated medical device.

For example, regulated apps are ones that allow a physician to make a diagnosis via smartphone or tablet, or apps that turn a smartphone into an electrocardiography machine to detect abnormal heart rhythms.

The guidelines come at a time of unprecedented growth in the mobile health app space, and a time when many developers are looking for regulatory guidance to make a successful product. President Obama signed legislation last July allowing the FDA to continue developing mobile health regulations. The guidelines were based on previous regulatory drafts.

[ Check out these mobile health apps from the government: 10 Mobile Health Apps From Uncle Sam. ]

The two categories of apps that won't be regulated are apps that aren't medical devices, and apps that might meet the definition of a medical device but pose a low risk to the public. Apps that will not be regulated include apps that:

-- help patients manage their disease or conditions without providing specific treatment;

-- provide patients with simple tools to organize and track their health information;

-- provide easy access to information related to patients' health conditions or treatments;

-- help patients document, show or communicate potential medical conditions to healthcare providers;

-- automate simple tasks for health care providers; or

-- enable patients or providers to interact with personal health record or electronic health record systems.

The regulatory criterion for whether an app qualifies as a "device" is intended use, as revealed by labeling claims, advertising materials or statements by manufacturers. The app is considered a "device" if its intention is to diagnose, treat or prevent disease, or affect the function of the body.

Apps that are an extension of medical devices, such as the remote display of data from bedside monitors or the display of medical images, are subject to regulation.

Class I, or low-risk, apps must include adequate design controls, registration, device listing, adverse event reporting, and corrections and removals. These apps are used as a secondary display to a regulated medical device and are not intended to provide primary diagnosis or treatment decisions. Class II requires more specific control and Class III requires pre-market approval.

The FDA has cleared about 100 medical apps over the past decade, with about 40 of those cleared in the past two years.

"Some mobile apps carry minimal risks to consumers or patients, but others can carry significant risks if they do not operate correctly," said Jeffrey Shuren, director of the FDA's Center for Devices and Radiological Health. "The FDA's tailored policy protects patients while encouraging innovation."

Comment  | 
Print  | 
More Insights
Comments
Newest First  |  Oldest First  |  Threaded View
ChrisMurphy
50%
50%
ChrisMurphy,
User Rank: Author
9/24/2013 | 9:58:07 PM
re: FDA Reveals Final Mobile Health App Guidelines
Also key to watch if it creates barriers to startups -- will innovators avoid regulated areas, or be drawn to them as more defensible?
dbtinc
50%
50%
dbtinc,
User Rank: Apprentice
9/24/2013 | 1:00:32 PM
re: FDA Reveals Final Mobile Health App Guidelines
It will of course be more expensive but non-compliance to a guideline may result in FDA not approving (clearing) the device. It also sets up a greater risk of product liability as well.
dbtinc
50%
50%
dbtinc,
User Rank: Apprentice
9/24/2013 | 12:59:43 PM
re: FDA Reveals Final Mobile Health App Guidelines
deviation from guidelines in the absence of information explaining why non-compliance to a guideline usually will result in non-approval of a new or improved medical device or regulatory action against a cleared device.
Thomas Claburn
50%
50%
Thomas Claburn,
User Rank: Author
9/24/2013 | 4:06:25 AM
re: FDA Reveals Final Mobile Health App Guidelines
I'll be interested to see what it costs to develop a regulated app as opposed to a non-regulated one.
David F. Carr
50%
50%
David F. Carr,
User Rank: Author
9/23/2013 | 11:30:50 PM
re: FDA Reveals Final Mobile Health App Guidelines
Are these binding guidelines? Do we have any idea how many apps currently on the market might be in violation of them?
Register for InformationWeek Newsletters
White Papers
Current Issue
InformationWeek Tech Digest September 24, 2014
Start improving branch office support by tapping public and private cloud resources to boost performance, increase worker productivity, and cut costs.
Video
Slideshows
Twitter Feed
InformationWeek Radio
Sponsored Live Streaming Video
Everything You've Been Told About Mobility Is Wrong
Attend this video symposium with Sean Wisdom, Global Director of Mobility Solutions, and learn about how you can harness powerful new products to mobilize your business potential.